Destiny Pharma plc
("Destiny Pharma" or "the Company")
Destiny Pharma Appoints Stephanie Bewick as Chief Business Officer
Brighton, United Kingdom - 6th January 2021 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces the appointment of Dr Stephanie Bewick as Chief Business Officer.
Dr Bewick brings 20 years' experience in business development at public and private biotech companies as well as mid-sized pharma, both in-house and as a consultant. Most recently, she was Vice President, Business Development at Summit Therapeutics, a NASDAQ-listed infectious disease company, leading the out-licensing and in-licensing activities, pipeline positioning and technology valuation. She holds a BSc (Hons) Neuroscience from the University of Edinburgh and a PhD from the University of Bristol.
Neil Clark, Chief Executive Officer of Destiny Pharma, said: "I am very pleased to welcome Stephanie to Destiny Pharma. She brings a wealth of experience and a proven track record in business development and deal making having completed a range of transactions including in the anti-infectives space. Her expertise will be invaluable to Destiny Pharma as we look to maximise the value of our two late-stage clinical assets and in building a world leading anti-infection company."
Stephanie Bewick, Chief Business Officer of Destiny Pharma, added: "This is a very exciting time to join Destiny Pharma after such a transformational year. Destiny Pharma has a fantastic XF platform and biotherapeutic/microbiome pipeline with unique late-stage clinical assets. I look forward to working with Neil and the team to progress the vibrant pipeline."
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
DestinyPharma@optimumcomms.com
+44 (0) 203 174 1789
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
